NASDAQ:GLYC - Nasdaq - US38000Q1022 - Common Stock - Currency: USD
0.157
-0.01 (-5.42%)
The current stock price of GLYC is 0.157 USD. In the past month the price decreased by -37.15%. In the past year, price decreased by -40.3%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.43 | 334.34B | ||
AMGN | AMGEN INC | 14.37 | 160.37B | ||
GILD | GILEAD SCIENCES INC | 14.44 | 139.01B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.03B | ||
REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 43.28B | ||
ARGX | ARGENX SE - ADR | 94.52 | 33.18B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.26 | 26.56B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.44B | ||
NTRA | NATERA INC | N/A | 22.09B | ||
BIIB | BIOGEN INC | 8.4 | 19.47B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.23B |
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The firm was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.
GLYCOMIMETICS INC
9708 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Rachel K. King
Employees: 4
Phone: 12402431201
The current stock price of GLYC is 0.157 USD. The price decreased by -5.42% in the last trading session.
The exchange symbol of GLYCOMIMETICS INC is GLYC and it is listed on the Nasdaq exchange.
GLYC stock is listed on the Nasdaq exchange.
GLYCOMIMETICS INC (GLYC) has a market capitalization of 10.13M USD. This makes GLYC a Nano Cap stock.
GLYCOMIMETICS INC (GLYC) currently has 4 employees.
GLYCOMIMETICS INC (GLYC) has a resistance level at 0.22. Check the full technical report for a detailed analysis of GLYC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLYC does not pay a dividend.
GLYCOMIMETICS INC (GLYC) will report earnings on 2025-08-06.
GLYCOMIMETICS INC (GLYC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).
ChartMill assigns a fundamental rating of 2 / 10 to GLYC. GLYC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GLYC reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 34.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -341.52% | ||
ROE | -712.87% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to GLYC. The Buy consensus is the average rating of analysts ratings from 7 analysts.